Compare XNCR & RERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNCR | RERE |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 859.3M |
| IPO Year | 2013 | 2021 |
| Metric | XNCR | RERE |
|---|---|---|
| Price | $12.85 | $5.77 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $22.78 | N/A |
| AVG Volume (30 Days) | 794.1K | ★ 1.6M |
| Earning Date | 02-26-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.16 |
| Revenue | $150,132,000.00 | ★ $2,759,212,837.00 |
| Revenue This Year | $18.68 | $30.64 |
| Revenue Next Year | N/A | $24.84 |
| P/E Ratio | ★ N/A | $35.18 |
| Revenue Growth | ★ 38.16 | 27.95 |
| 52 Week Low | $6.92 | $2.00 |
| 52 Week High | $21.00 | $6.47 |
| Indicator | XNCR | RERE |
|---|---|---|
| Relative Strength Index (RSI) | 33.77 | 56.01 |
| Support Level | $13.77 | $5.21 |
| Resistance Level | $15.40 | $6.47 |
| Average True Range (ATR) | 0.79 | 0.27 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 0.00 | 47.33 |
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.